Loading…
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.3B | $160M | $128M | $57M | 23.7% | 59.0% | 1.8% |
| 2024 | $1.5B | $79M | $126M | $198M | 26.4% | 69.3% | -635.3% |
| 2023 | $872M | $-20M | $-24M | $47M | -6.8% | 65.5% | -64.1% |
| 2022 | $527M | $-61M | $-66M | $-34M | -21.1% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 526.92 | 872 | 1,476.51 | 2,347.64 |
| Operating Revenue | - | 526.92 | 872 | 1,476.51 | 2,347.64 |
| Cost Of Revenue | - | 118.19 | 157.05 | 303.38 | 614.26 |
| Gross Profit | - | 408.72 | 714.95 | 1,173.14 | 1,733.38 |
| Operating Expense | - | 477.42 | 744.40 | 1,111.23 | 1,627.76 |
| Research And Development | - | 29.24 | 48.23 | 78.82 | 149.30 |
| Selling General And Administration | - | 370.78 | 576.32 | 846.61 | 1,192.02 |
| Total Expenses | - | 595.61 | 901.45 | 1,414.61 | 2,242.02 |
| Operating Income | - | -68.70 | -29.45 | 61.90 | 105.61 |
| Total Operating Income As Reported | - | -68.70 | -29.45 | 61.90 | 105.61 |
| EBITDA | - | -61.22 | -19.94 | 78.99 | 160.12 |
| Normalized EBITDA | - | -61.22 | -19.94 | 78.99 | 155.68 |
| EBIT | - | -68.70 | -29.45 | 61.90 | 105.61 |
| Interest Expense | 0 | - | - | - | - |
| Net Interest Income | 0 | - | - | - | - |
| Other Non Operating Income Expenses | - | 2.99 | 7.88 | 9.81 | 13.87 |
| Other Income Expense | - | 2.99 | 7.88 | 9.81 | 18.31 |
| Interest Expense Non Operating | 0 | - | - | - | - |
| Net Non Operating Interest Income Expense | 0 | - | - | - | - |
| Pretax Income | - | -65.71 | -21.57 | 71.71 | 123.92 |
| Tax Provision | - | -0.03 | 1.98 | -54.33 | -4.44 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0.93 |
| Net Income Continuous Operations | - | -65.68 | -23.55 | 126.04 | 128.36 |
| Net Income From Continuing And Discontinued Operation | - | -65.68 | -23.55 | 126.04 | 128.36 |
| Net Income From Continuing Operation Net Minority Interest | - | -65.68 | -23.55 | 126.04 | 128.36 |
| Net Income | - | -65.68 | -23.55 | 126.04 | 128.36 |
| Net Income Common Stockholders | - | -65.68 | -23.55 | 126.04 | 128.36 |
| Net Income Including Noncontrolling Interests | - | -65.68 | -23.55 | 126.04 | 128.36 |
| Normalized Income | - | -65.68 | -23.55 | 126.04 | 124.86 |
| Diluted NI Availto Com Stockholders | - | -65.68 | -23.55 | 126.04 | 128.36 |
| Basic Average Shares | - | 204.52 | 209.34 | 215.94 | 224.96 |
| Diluted Average Shares | - | 204.52 | 209.34 | 236.81 | 258.23 |
| Reconciled Depreciation | - | 7.47 | 9.52 | 17.09 | 54.50 |
| Reconciled Cost Of Revenue | - | 118.19 | 157.05 | 303.38 | 614.26 |
| Total Unusual Items | 3.80 | 0.07 | - | - | 4.44 |
| Total Unusual Items Excluding Goodwill | 3.80 | 0.07 | - | - | 4.44 |
| Gain On Sale Of Security | 3.80 | 0.07 | - | - | 4.44 |
| General And Administrative Expense | - | 98.19 | 129.88 | 167.77 | 272.72 |
| Other Gand A | - | 98.19 | 129.88 | 167.77 | 272.72 |
| Other Operating Expenses | - | 77.40 | 119.86 | 185.80 | 286.44 |
| Selling And Marketing Expense | - | 272.59 | 446.44 | 678.84 | 919.30 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Hims & Hers Health, Inc.this co. | HIMS | $6.5B | 50.51 | 11.99 | 23.7% | 46.06 |
| Apogee Therapeutics, Inc. | APGE | $6.9B | -26.79 | 7.58 | -28.3% | -23.68 |
| Spyre Therapeutics, Inc. | SYRE | $6.8B | - | 9.53 | -21.7% | - |
| Arcellx, Inc. | ACLX | $6.7B | -29.41 | 16.73 | -56.9% | -30.17 |
| Immunovant, Inc. | IMVT | $6.7B |
| - |
| - |
| - |
| - |
| - |
| - |
| -13.27 |
| 7.87 |
| -59.3% |
| -10.90 |
| Lantheus Holdings, Inc. | LNTH | $6.7B | 28.66 | 6.14 | 21.4% | 17.23 |
| Kymera Therapeutics, Inc. | KYMR | $6.1B | - | 3.89 | -19.7% | - |
| Terns Pharmaceuticals, Inc. | TERN | $6.1B | -63.58 | 6.08 | -9.6% | -51.02 |
| Rhythm Pharmaceuticals, Inc. | RYTM | $6.0B | - | 22.25 | -74.8% | - |
| Peer Median | - | -26.79 | 7.72 | -25.0% | -23.68 | |